Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform
dc.contributor.author | Majoros, István J. | en_US |
dc.contributor.author | Williams, Christopher R. | en_US |
dc.contributor.author | Becker, Andrew | en_US |
dc.contributor.author | Baker, James R. Jr. | en_US |
dc.date.accessioned | 2009-09-02T14:37:57Z | |
dc.date.available | 2010-10-05T18:27:29Z | en_US |
dc.date.issued | 2009-09 | en_US |
dc.identifier.citation | Majoros, IstvÁn J.; Williams, Christopher R.; Becker, Andrew; Baker, James R. (2009). "Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform." Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 1(5): 502-510. <http://hdl.handle.net/2027.42/63594> | en_US |
dc.identifier.issn | 1939-5116 | en_US |
dc.identifier.issn | 1939-0041 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63594 | |
dc.description.abstract | This paper provides a synopsis of the advancements made in advancing a dendrimer-based nanomedicine towards human clinical trials by the Michigan Nanotechnology Institute for Medicine and Biological Sciences. A brief description of the synthesis and characterization of a targeted multifunctional therapeutic will demonstrate the simple yet delicate task of producing novel chemotherapeutic agents. The results obtained from in vitro and in vivo studies not only authenticate the potential of using nanoparticles to target therapeutics but also provide valuable insight towards the future directions of this technology. A fundamental, cross-disciplinary collaboration was necessary to achieve the synthesis and testing of this technology, and was the keystone to establishing this innovative invention. Throughout this paper, we will stress that the unique collaboration that facilitated the evolution of this technology is vital to the success of future developments in nanomedicine. Copyright © 2009 John Wiley & Sons, Inc. | en_US |
dc.format.extent | 348777 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Medicine | en_US |
dc.subject.other | Nanotechnology & Nanomaterials | en_US |
dc.title | Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Biomedical Engineering | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109-0533, USA ; Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109-0533, USA | en_US |
dc.contributor.affiliationum | Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109-0533, USA | en_US |
dc.contributor.affiliationum | Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109-0533, USA | en_US |
dc.contributor.affiliationum | Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109-0533, USA | en_US |
dc.identifier.pmid | 20049813 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63594/1/37_ftp.pdf | |
dc.identifier.doi | 10.1002/wnan.37 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.